This work is licensed under a Creative Commons Attribution 4.0 International License.
PE-BBI
General Information
DRACP ID DRACP00839
Peptide Name PE-BBI
Sequence GALKGCWTKSIPPKPCK
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin skin secretion of Pelophylax esculentus (PE) named PE-BBI
Type Native peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| DLD-1 | Colon adenocarcinoma | Carcinoma | IC50=50.1 μM | MTT assay | 24h | 1 |
| DKs-8 | Colon adenocarcinoma | Carcinoma | IC50=9.8 μM | MTT assay | 24h | 1 |
| HCT 116 | Colon carcinoma | Carcinoma | IC50=35.4 μM | MTT assay | 24h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HKE3: IC50=50.2 μM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C82H136N22O20S2
Absent amino acids DEFHMNQRVY
Common amino acids K
Mass 209981
Pl 10.35
Basic residues 4
Acidic residues 0
Hydrophobic residues 4
Net charge 4
Boman Index -975
Hydrophobicity -50
Aliphatic Index 51.76
Half Life
Mammalian: 1.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 5625
Absorbance 280nm 351.56
Polar residues 6
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30267012
Title Identification and pharmaceutical evaluation of novel frog skin-derived serine proteinase inhibitor peptide-PE-BBI (Pelophylax esculentus Bowman-Birk inhibitor) for the potential treatment of cancer
Doi 10.1038/s41598-018-32947-5
Year 2018
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.